Oligopin Supplementation and Bone Turnover Markers and Antioxidant Changes in Postmenopausal Osteopenic Women

NCT03260803 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Osteopenia

Interventions

DRUG: Oligopin
DRUG: Placebo

Sponsor

Tehran University of Medical Sciences

Collaborators

[object Object]